Name: SPERO THERAPEUTICS INC (SPRO) Stock
Brand: SPERO THERAPEUTICS INC
Rating: 5 (3 reviews)

SPRO Latest News, Press Relases and Analysis

All

Press Releases

3 hours ago - By: Chartmill

Spero Therapeutics Inc (NASDAQ:SPRO) Posts Q3 Revenue and EPS Beat

7 hours ago - By: Spero Therapeutics, Inc.

Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update

24 days ago - By: Spero Therapeutics, Inc.

PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)

3 months ago - By: Zacks Investment Research

Down 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a Turnaround

3 months ago - By: Benzinga - Mentions: SBFM AZTA DERM XAIR ...

12 Health Care Stocks Moving In Tuesday's After-Market Session

3 months ago - By: Spero Therapeutics, Inc.

Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update

3 months ago - By: Benzinga

Earnings Outlook For Spero Therapeutics

3 months ago - By: Spero Therapeutics, Inc.

Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025

6 months ago - By: Yahoo Finance - Mentions: DHI CMG

Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone

6 months ago - By: Zacks Investment Research - Mentions: GSK AGEN ADPT

SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal

6 months ago - By: Stocktwits - Mentions: GSK VTI

GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled

6 months ago - By: Bloomberg

GSK Stops Antibiotic Trial Early After Seeing Positive Results

6 months ago - By: Spero Therapeutics, Inc.

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update

6 months ago - By: Zacks Investment Research - Mentions: QURE

UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

6 months ago - By: Zacks Investment Research - Mentions: RNA

Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates

6 months ago - By: Zacks Investment Research - Mentions: MIRM

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates

7 months ago - By: Spero Therapeutics, Inc.

Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

8 months ago - By: Zacks Investment Research - Mentions: NRIX

Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates

8 months ago - By: Spero Therapeutics, Inc.

SPERO THERAPEUTICS INC (SPRO) Stock News